Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Professor Alexander Eggermont, general director of Gustave Roussy, gives insights into the transformation of the Hospital under his ten-year leadership mandate. He also explains the rationale behind creating Cancer Core…
Jean-Luc Belingard, president of FEFIS (Fédération Française des Industries de Santé – French Federation of the Health Industry), explains his role following up on the implementation of the CSIS (Conseil…
Jean-Yves Berthon, CEO of French plant biotechnology pioneers GREENTECH discusses the key milestones in the company’s development trajectory, diversification plans and potential M&A activity. Our speciality is the extraction,…
Eric Del Cotto, general manager of Owen Mumford Southern Europe and Northern Africa, explains the challenges in market access for SMEs in France. He also gives an overview of Owen…
LEEM – Les Entreprises du Médicament (Drug Companies) Key people: Philippe Tcheng, President Philippe Lamoureux, Director LEEM is the French industry association which represents drug companies operating in France…
ANSM – Agence Nationale de Sécurité des Médicaments et des Produits de Santé (National Agency for the Safety of Drugs and Health Products) Key People: Dominique Martin, CEO The National Agency…
Marc Julien, co-CEO of Diabeloop, presents the revolutionary “artificial pancreas” the company has developed to support type one diabetes patients. The device embeds artificial intelligence to help type one diabetics…
Vincent Poher, founder of Avalun, explains the key technology behind the establishment of the company as well as their forthcoming expansion strategy. He also outlines the main challenges start-ups can…
In an exclusive interview, Yves L’Epine, president of G5 Santé and CEO of Guerbet, offers his insider take on the business climate in French healthcare and the potential for France…
INCa – Institut National du Cancer (The National Cancer Institute) The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in…
DSS Direction de la Sécurité (Department of Social Security) Key People: Director General Mathilde Lignot-Leloup The Directorate of Social Security (DSS) supervises all social security organizations: general scheme funds,…
Commission des Affaires Sociales de l’Assemblée Nationale (Commission of Social Affairs, National Assembly) Key People: Brigitte Bourguignon, Chairwoman Olivier Véran, General Reporter The Social Affairs Committee of the National Assembly is…
See our Cookie Privacy Policy Here
